Literature DB >> 21112532

Overexpression of cyclooxygenase-2 as a biomarker in different subtypes of the oral lichenoid disease.

Dionisio A Cortés-Ramírez1, María J Rodríguez-Tojo, María L Gainza-Cirauqui, Rafael Martínez-Conde, José M Aguirre-Urizar.   

Abstract

OBJECTIVE: Oral lichenoid disease (OLD) includes a number of chronic inflammatory processes including oral lichen planus (OLP) and oral lichenoid lesions (OLL) with controversial diagnosis and prognosis. Cyclooxygenase-2 (COX-2) is a key enzyme for inflammatory processes and cellular proliferation. Its overexpression in some premalignant chronic inflammatory diseases and malignant neoplasias could point to its potential as a prognostic factor. The aim of this study was to analyze the COX-2 expression in different subtypes of OLD because of its potential to be a marker of altered behavior. STUDY
DESIGN: Forty-four samples from OLD patients were studied (30 females and 14 males) and classified according to their clinical (C1: only papular lesions/C2: papular and other lesions) and histological features (HT: OLP typical/HC: OLP compatible) according to published criteria. Standard immunohistochemical procedure was performed for COX-2 expression and a comparative and descriptive statistical analyses were performed.
RESULTS: Epithelial COX-2 overexpression was observed in 24 (54.5%) cases (C1: 13 [54.2%]/C2: 11 [45.8%], HT: 9 [37.5%]/HC: 15 [62.5%], P = .032). Inflammatory COX-2 overexpression was observed in 14 (31.8%) cases (C1: 6 [42.9%]/C2: 8 [57.1%], HT: 4 [28.6%]/HC: 10 [71.4%], P = .032).
CONCLUSION: Differences in COX-2 expression in subtypes of OLD may distinguish cases with a higher premalignant potential.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112532     DOI: 10.1016/j.tripleo.2010.08.005

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  6 in total

Review 1.  Black pepper and its bioactive constituent piperine: promising therapeutic strategies for oral lichen planus.

Authors:  Jing-Ya Yang; Jing Zhang; Gang Zhou
Journal:  Inflammopharmacology       Date:  2018-10-20       Impact factor: 4.473

2.  Expression of Ki-67, p53, α-SMA and COX-2 in lichen planus and related lesions: A pilot study.

Authors:  D S Sanketh; Karuna Kumari; Roopa S Rao; Vanishree C Haragannavar; Sachin C Sarode; Gargi S Sarode; A Thirumal Raj; Shankargouda Patil
Journal:  J Oral Biol Craniofac Res       Date:  2018-02-19

Review 3.  Oral lichenoid lesions - a review and update.

Authors:  Venkatesh Vishwanath Kamath; Krishnanand Setlur; Komali Yerlagudda
Journal:  Indian J Dermatol       Date:  2015 Jan-Feb       Impact factor: 1.494

4.  Increased cyclooxygenase 2 expression in association with oral lichen planus severity.

Authors:  Thaneeya Chankong; Pareena Chotjumlong; Thanapat Sastraruji; Surawut Pongsiriwet; Anak Iamaroon; Suttichai Krisanaprakornkit
Journal:  J Dent Sci       Date:  2016-04-08       Impact factor: 2.080

5.  Expression of COX-2 and bcl-2 in oral lichen planus lesions and lichenoid reactions.

Authors:  Alven J Arreaza; Helen Rivera; María Correnti
Journal:  Ecancermedicalscience       Date:  2014-03-20

6.  Epidermal growth factor receptor expression in different subtypes of oral lichenoid disease.

Authors:  Dionisio-Alejandro Cortés-Ramírez; María-Jose Rodríguez-Tojo; Juan-Carlos Coca-Meneses; Xabier Marichalar-Mendia; José-Manuel Aguirre-Urizar
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2014-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.